Intended for Canadian Healthcare Professionals Only

About Collagenase SANTYL® Ointment

SANTYL Ointment

SANTYL® Ointment – Continuous, Active Micro-Debridement

SANTYL® Ointment is a Health Canada approved active enzymatic therapy that continuously removes necrotic tissue from wounds at the microscopic level.
This works to free the wound bed of microscopic cellular debris, allowing granulation to proceed and epithelialization to occur.1-3

SANTYL® Ointment contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium hystolyticum.

SANTYL® Ointment is appropriate for both initial debridement and continuous debridement after sharp or surgical debridement.

Continuous, Active Micro-Debridement

The SANTYL® Ointment advantage is its continuous, active debridement. Unlike macroscopic methods of debridement (sharp and surgical), SANTYL® Ointment continuously removes necrotic tissue, maintaining a clean wound bed. By taking an active approach instead of a passive one (e.g., autolytic debridement), SANTYL® Ointment enables debridement of chronic wounds, even for geriatric patients and those with compromised immune status.1,2

SANTYL® Ointment is indicated for the debridement of 4-7:

  • Pressure ulcers
  • Diabetic ulcers
  • Venous leg ulcers
  • Severely burned areas
  • SANTYL® Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase

Effectiveness in Clinical Studies

SANTYL® Ointment has been proven clinically efficacious in a number of studies in a variety of wound types4-16:

  • Demonstrated superiority to placebo in the debridement of dermal ulcers
  • Demonstrated superiority to standard antimicrobial therapy alone and combination with topical antimicrobial therapy in the debridement of severe burns
  • Well tolerated in the debridement of both soft tissue ulcers and severe burns


MOA Video

Occasional slight transient erythema has been noted in surrounding tissue when applied outside the wound. One case of systemic hypersensitivity has been reported after 1 year of treatment with collagenase and cortisone.
Use of Collagenase SANTYL® Ointment should be terminated when debridement is complete and granulation tissue is well established.
See complete prescribing information for more details.

References: 1. Ayello EA, Cuddigan JE. Debridement: Controlling the necrotic/cellular burden. Adv Skin Wound Care. 2004;17:66-75. 2. Milne CT, Corbett LQ. (ed). Wound, Ostomy and Continence Nursing Secrets. Philadelphia, PA: Hanley & Belfus, 2003. 3. Shi L, Carson D. Collagenase Santyl ointment: a selective agent for wound debridement. J Wound Ostomy Continence Nurs. 2009;36(6 Suppl)S12-S16. 4. Lee LK, Ambrus JL. Collagenase therapy for decubitus ulcers. Geriatrics. 1975;30:91-98. 5. Altman MI, Goldstein L, Horowitz S. Collagenase: an adjunct to healing trophic ulcerations in the diabetic patient. J Am Podiatry Assoc. 1978;68:11-15. 6. Boxer AM, Gottesman N, Bernstein H, et al. Debridement of dermal ulcers and decubiti with collagenase. Geriatrics. 1969;24:75-86. 7. Hansbrough JF, Achauer B, Dawson J, et al. Wound healing in partial-thickness burn wounds treated with collagenase ointment versus silver sulfadiazine cream. J Burn Care Rehabil. 1994;15:13-17. 8. Varma A, Bugatch E. Debridement of dermal ulcers with collagenase. Surg Gynecol Obstet. 1973;136:281-282. 9. Barrett D, Klibanski A. Collagenase debridement Amer J Nursing. 1973;73:849-851. 10. Blum G. Therapeutic evaluation of debriding agent in dermal ulcers, decubitus ulcers, and burns. Derm Digest. 1974;36. 11. Vetra H, Whittaker D. Hydrotherapy and topical collagenase for decubitus ulcers. Geriatrics. 1975;30:53-58. 12. Rao DB, Sane PG, Georgiev EL. Collagenase in the treatment of dermal and decubitus ulcers. J Am Geriatr Soc. 1975;23:22-30. 13. Zaruba F, Lettl A, Borzkova L, Skrdlantova H, Krs V. Collagenase in the treatment of ulcers in dermatology. J Hyg Epidemiol Microbiol Immunol. 1974;18:499-500. 14. Haimovici H, Strauch B. Use of collagenase in the management of stasis and ischemic ulcers of the lower extremities. In: Mandl I, ed. Collagenase. New York, NY: Gordon and Breach Science Publishers. 1971:177-183. 15. Vrabec R, Moserova J, Konickova Z, Behounkova E, Blaha J. Clinical experience with enzymatic debridement of burned skin with the use of collagenase. J Hyg Epidemiol Microbiol Immunol. 1974;18:496-497. 16. Soroff HS, Sasvary DH. Collagenase ointment and polymixin B sulfate/bacitracin spray versus SILVADENE® cream in partial thickness burns: a pilot study. J Burn Care Rehabil. 1994;15:13-17.
Mechanism of Action Video

moa video
Application Protocol for
SANTYL® Ointment

learn more link

Answers to Frequently Asked
Questions About SANTYL®
learn more link
SANTYL® is a registered trademark of Healthpoint Biotherapeutics. Healthpoint Biotherapeutics and design is a registered trademark of Healthpoint Biotherapeutics.
© 2010 Healthpoint Canada ULC. All rights reserved.
The information on this site is intended for customers, patients, and healthcare professionals in Canada only. All information, including the Prescribing Information for Collagenase SANTYL® Ointment, abides by the laws, regulatory requirements, and medical practices for Canada only and may not be appropriate for use outside of Canada.